INTRODUCTION

In the last 40 years, treatment of head and neck squamous cell cancer (HNSCC) did not change dramatically. Radiotherapy and platinum-based chemotherapy represent the backbone treatments for locally advanced HNSCC (LA-HNSCC) and are offered for resected high-risk LA-HNSCC [1-5]. In 2006, the trial by Bonner et al. [6] introduced a second standard treatment: bio-radiation. Relapsed metastatic head and neck cancer (RM-HNC) evolved even slower than LA-HNC.

Platinum combination was the standard treatment until the extreme study reported the benefit of Cetuximab combination [7]. Since then, the extreme regimen represents the new first-line standard of care for RM-HNC. An established second-line treatment has never existed in RM-HNC, up to the approval of immune checkpoint inhibitors (ICIs) [8]. Therefore, the 5-year prognosis remains around 50% at 5 years and median overall survival (OS) in RM-HNC is less than 11 months [7].

However, immune-modulating treatments appear to have a clear clinical benefit for RM-HNSCC and this benefit seems to be independent of previous treatment, even being observed among patients who have received multiple lines of therapy and who have been assumed to have exhausted all options. Two drugs targeting the PD-1/PD-L1 axis, Nivolumab and pembrolizumab, have achieved the approval for second-line treatment of RM-HNC (study KEYNOTE-012 [9] and CheckMate 141 [10]) [11]. Moreover, Durvalumab, an anti-PD-L1 drug, also showed a benefit in terms of disease control rate in pretreated HNSCC patients [12].

It is reasonable to think that these ICIs will move soon to first-line and will be introduced as companion drugs in the multi-agent treatment of LA-HNC. In the meanwhile, new immunotherapies are in clinical development and some of them have already reached the phase III [11]. However, although the results (slightly higher but longer responses) justify the enthusiasm, they are some warning on immune-resistance. Indeed, a high proportion of patients is resistant or acquires resistance to these therapeutic strategies. The latter findings may reflect, at least in some cases, the inability of the immunotherapeutic strategies used to eradicate (Table 1 summarizes published results with ICI in HNSCC; Table 2 reports a confront with standard methotrexate as published in LUX1 study) [9,10,13-15]. This paper addresses the new data on the therapy of HNSCC and discusses the biological basis of immunotherapy in this disease.
THE MUTATIONAL LOAD AND THE EFFECT OF THE VIRAL ETIOLOGY ON THE RESPONSE TO THE ICIs

According to Blank et al. [16], the mutational load (ML) of HNC is in between liver cancer and kidney cancer, tumors known for their high immunogenicity. This is related to the large number of mutations induced by smoking, the upmost risk factor for these tumors. However, the head and neck regions host two different virus-induced tumors: oropharynx cancer, related to human papillomavirus (HPV), and undifferentiated nasopharynx cancer, related to Epstein-Barr Virus (EBV).

Looking at environmental induced tumors, it is expected that they are able to generate robust immune response, as supported by the high immune cells infiltration, due to their high ML [17]. Virus-induced HNC are different from the environmental-induced HNC. For example, both the virus-induced tumors show a much lower ML rather than those related to smoking abuse [18,19]. According to Seiwert et al. [19], there is a direct relationship between ML and benefit from immunotherapy. However, clinical available data do not show any clear difference of the outcome between “environmental” and “virus-related” HNC. Generically, we might speculate that the virus immunogenicity could compensate for the lower mutational burden of virus induced HNC. Indeed, invading DNA viruses or transfected DNA, activate stimulator of interferon genes (STING), a signaling molecule located in the endoplasmic reticulum, leading to the transcription of many immune genes. This in turn promotes an immune response against pathogens and cancer cells starting an interferon (IFN) type I over expression which is toll-like receptor (TLR) independent [20]. In addition, STING, different from the TLRs, is widely expressed in various cell types, including endothelial, epithelial and haemopoietic, such as T cells, dendritic cells dendritic cells (DCs), and in particular, plasmacytoid DCs [21].

Table 1. Study population and activity

| Study          | No. of patients | Treat  | Line | ORR                  | PFS/OS | CR/PR | HPV  |
|----------------|-----------------|--------|------|----------------------|--------|-------|------|
| KEYNOTE-012    | Seiwert et al. (2016) [13] | 60     | PEM  | >1 21%, 12.2-Month duration of response | NR     | NR    | 23 Patients |
| KEYNOTE-012    | Chow et al. (2016) [9] | 132    | PEM  | >1, 82%; 1° line, 18% | 18% wp | 32% (HPV positive) | 22% (PD-L1 positive) | 4% (PD-L1 negative) | 6 mo PFS 23% OS 59% | NR | 28 Patients |
| CheckMate 141  | Ferris et al. (2016) [10] | 361    | Nivo vs. SOC | II | 17% (PD-L1 positive) 12.3% (PD-L1 negative) 15.9% (p16 positive) 8% (p16 negative) | 1 yr 16%/36% PFS 2 mo, OS 7.5 mo | 6/26 | 275 Patients |
| Durvalumab     | Segal et al. (2016) [12] | 51     | Durvalumab III | 12% wp 25% (PD-L1 positive) | NR | NR | NR |
| KEYNOTE-040    | Cohen et al. (2017) [14] | 495    | PEM vs. SOC | III | NR | 2.1 mo/8.4 mo | 1/24 | NR |

ORR, overall response rate; PFS, progression-free survival; OS, overall survival; CR, complete response; PR, partial response; HPV, human papillomavirus; PEM, pembrolizumab; NR, not reported; wp, whole population; Nivo, Nivolumab; SOC, standard of care.

Table 2. Activity compared with second line

| Outcome | CheckMate 141 Nivo | CheckMate 141 SOC | KEYNOTE-040 PEM | KEYNOTE-040 SOC | LUX H-N 1 afatinib | LUX H-N 1 methotrexate |
|---------|---------------------|-------------------|-----------------|-----------------|-------------------|----------------------|
| mPFS (mo) | 2.0                 | 2.3 (3.0)         | 2.3             | 2.3             | 2.5               | 1.7 |
| mOS (mo)  | 7.5                 | 5.1 (4.8)         | 7.1             | 6.8             | 6.0               | 6.0 |
| mPFS PD-L1 positive (mo) | -                   | 2.2 (3.5)         | 2.3 (2.2)       | 2.6              | 1.7 |
| mOS PD-L1 positive (mo)  | 8.7                 | 4.6 (4.0)         | 7.1 (7.9)       | 6.8              | 6.0 |

Nivo, Nivolumab; SOC, standard of care; PEM, pembrolizumab; H-N, head & neck; mPFS, median progression-free survival; mOS, median overall survival. *mPFS and mOS for patients with PD-L1 >50% in tumor prognostic score are in the parenthesis.
ICI COMBINATIONS

Combining anti-PD-1 and anti-CTLA-4 agents has been approved for melanoma, and it looks promising in lung cancer and renal cancer [22]. Several studies are ongoing both in first- and second-line combining anti-PD-1 and anti-CTLA-4. Immuno-oncology regimens for HNSCC have yielded modest results, with few good responders (long-lasting and tumor response) [11]. It may be hypothesized that monotherapy is not able to overcome the numerous mechanism of immune escape. Combinatorial immunotherapy should increase response based on biological rationale of acting at a different ligand and function. It has been reported that HNSCCs have a high infiltration of Tregs, so although inflamed tumor immune phenotype, response might be unsatisfactory. Moreover, in immune excluded tumor, microenvironment is rich of immunosuppressive factors that avoid immune response (high interstitial pressure due to vascular endothelial growth factor [VEGF], metabolic alteration due to indoleamine 2, 3-dioxygenase [IDO], natural killer impairment related to several other immune regulators such as KIR, CD137, TIM3, LAG3) [23].

A promising approach is to combine IDO1 inhibitor with ICI: IDO1 over expression has been associated with poor survival in HNSCC. The role of this enzyme is very important, it transforms tryptophan in kynurenine, on the one hand, tryptophan deprivation affect cytotoxic lymphocytes, on the other hand, excess of kynurenine induce their apoptosis. Preliminary results of the combination epacadostat (a potent, selective oral IDO1 inhibitor) plus pembrolizumab reported encouraging response rates (34% and 14% in second and third lines and more heavily pretreated patients) [24]; epacadostat also demonstrated promising activity in combination with other checkpoint inhibitors in other solid tumors, including melanoma, uterine carcinoma, renal cell carcinoma, and non-small cell lung cancer. Recent advances demonstrated the role of STING, TLR and retinoic induced gene receptors like to induce effective response. However, although TLRs are key mediators of immune responses, TLR agonists in combination with bio and chemotheraphy failed to improve progression-free survival (PFS). In the Active 8 study, no advantage was reported with or without motolimod therapy, a selective small-molecule agonist of TLR8. It must be remembered that not all TLRs are the cytosolic and this might explain differences in efficacy [25]. Nevertheless, the combination of motolimod with Cetuximab in patients with HNSCC showed a disease control rate of 54% [26]. A phase IB is ongoing in the neoadjuvant setting.

COMBINATION WITH RADIOTHERAPY AND/OR CHEMOTHERAPY AND/OR ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR

Based on biologic knowledge, immunotherapy has been associated respectively with radiotherapy or chemotherapy in order to induce cancer death and a self-vaccination; with vaccination to target viral antigens and with biotherapy to target proliferation pathways that crosstalk with immune system. The rationale is to elicit a strong immune response activating microenvironment while administering immunotherapy [27]. Preclinical evidence showed that radiotherapy upregulates PD-L1 within 24 to 48 hours; in animal models increase in survival has been reported [28].

A second partner with a strong biological rationale is anti-epidermal growth factor receptor (EGFR) Cetuximab (Erbitux) (https://clinicaltrials.gov). Several demonstrations evidenced that at least a part of Cetuximab effect depends on antibody-mediated cytotoxicity, this activity involves principally natural killer cells. Eight studies are ongoing combining ICI+Cetuximab respectively with Nivolumab (two studies), Pembrolizumab (two studies), Durvalumab (three studies) and Avelumab (two studies) [29-32].

There are also at least three phase III trials for LA-HNC. Early reports confirmed that pembrolizumab in combination with weekly cisplatin-based chemoradiotherapy (CRT) is safe and does not significantly impair radiation or chemotherapy dosing (ClinicalTrials.gov Identifier: NCT02586207) [33]. The goal of this combination (ICI+CRT) is to increase distant metastases free survival and OS in stage III-IV HNC. These studies will inform on the correct algorithm: providing evidence if sequential versus concomitant ICI has to be preferred.

In the neoadjuvant setting, extraordinary results point out the time of ICI therapy: earlier than recurrent/metastatic (R/M) disease? Benefit after one dose of pembrolizumab before surgery was obtained in 48% of patients (95% confidence interval, 26% to 70%; ClinicalTrials.gov Identifier: NCT02296684) while after two doses of Nivolumab 11 of 23 patients reported RECIST (Response Evaluation Criteria in Solid Tumors) disease

Table 3. Phase III combination studies in LA-HNC as of October 2017

| Study        | No. of patients | Treatment                                      | Outcome | Expectation date |
|--------------|-----------------|------------------------------------------------|---------|------------------|
| Rtog3504     | 120             | Nivo+P+RT vs. Nivo+Cet+RT vs. Nivo+RT          | PFS     | Mar 2019         |
| KEYNOTE-412  | 780 HPV negative| PEM+P+RT vs. PRT                               | EFS     | Apr 2021         |
| JAVELIN H&N100 | 640            | Avelumab+PRT vs. PRT                           | PFS     | Apr 2021         |
| REACH        | 688             | PRT vs. avelumab+cetuximab+RT vs. Cet+RT       | PFS     | Dec 2018         |

LA-HNC, locally advanced head and neck cancer; Nivo, Nivolumab; P, platin; RT, radiotherapy; Cet, Cetuximab; PFS, progression-free survival; HPV, human papillomavirus; PEM, pembrolizumab; PRT, platinum radiotherapy; EFS, event-free survival.
Moreover, targeting HPV and EBV in association with ICI has showed enthusiastic preclinical results [35,36]. Several trials are ongoing combining definitive chemotherapy or CRT and HPV/EBV vaccines and ICI. Tables 3 and 4 summarize ongoing phase III trials in LA-HNC and RM-HNC.

### COST/BENEFIT OF IMMUNE CHECK-POINT INHIBITORS IN RM-HNC

Clinical trials (CheckMate 141, KEYNOTE-012, 055, 040) published (and presented) so far focus on second-line treatment. Lessons learned from these trials allow drawing some initial information on toxicity and activity [9,10-14,37].

### Patients population

A common feature of the patients included in these trials is the multiplicity of prior chemotherapy lines. Albeit the trials were designed for patients failing the first-line treatment, a large number of patients received immunotherapy as third or more treatment for their disease. In addition, most patients had Eastern Cooperative Oncology Group performance status 1 and were aged >80 years. The number of previous treatments and ages did not impact on safety and efficacy of treatment [38].

Although no clear data justify a selection of HPV positive patients, responses in some trials are higher than in HPV negative patients. Durvalumab in platinum refractory patients achieved a response of 26.5% in those HPV positive vs. 7.9% in those HPV negative [12]. However, these data are controversial as many HPV negative tumors are very immunogenic [39]. Pembrolizumab treatment leads to a better prognosis for HPV+HNSCC patients than for HPV-HNSCC patients [37].

### Toxicty

Toxicity is reported mild to moderate. Grade 3–4 adverse events (AEs) are consistently reported in less than 15% of the population (Table 5). However, information regarding the tolerance of specific subgroups at possible higher risk of toxicity, such as those with a history of allergy, is missing. Moreover, it is not known the evolution of endocrine-AEs in patients with basal radio-induced hypothyroidism (at least three of four patients treated with chemoradiation). Fatigue is the most reported side effect, but usually is limited to grade I–II. Overall, the reported toxicity seems strongly lower than expected with chemotherapy, in particular in the heavily pretreated population enrolled in these trials.

### Activity, PFS, OS

Average objective response rate is around 15%. This is larger than expected in second-line treatment (Tables 1, 2). However, activity remains well below desired and at least 80% of patients did not achieve any tumor size reduction. No significant difference between ICI and standard of care groups was observed with regard to the rate of PFS in both CheckMate and KEYNOTE studies; however, a late separation in the Kaplan-Meier was observed in these studies. Hyperprogression was observed in 29% of patients with RM-HNSCC treated with anti-PD-L1/ PD-1 agents and correlated with a shorter PFS [40]. Treatment evaluation is a challenge in this population. At European Society for Medical Oncology 2017 meeting, Haddad et al. [41] report-

### Table 4. Phase III combination studies in RM-HNC as of January 2018

| Study                  | Setting                  | Treatment                                                                 | Outcome   | Expectation date |
|------------------------|--------------------------|---------------------------------------------------------------------------|-----------|------------------|
| CheckMate 651 NCT 02741570 | 1st Line                | Nivo+IPI vs. Extreme                                                     | OS Safety | Jan 2019         |
| KESTREL NCT 02551159   | 1st Line                | Durvalumab vs. durvalumab+tremelimumab vs. Extreme                      | OS, PFS   | Mar 2018         |
| EAGLE NCT 02360874     | 1st Line +P-refractory  | Durvalumab vs. durvalumab+tremelimumab vs. Extreme                      | OS        | Feb 2018         |
| KEYNOTE-034            | 1st Line                | PEM+TVEC                                                                  | OS Safety | Dec 2018         |
| KEYNOTE-048            | 1st Line                | PEM vs. PEM+PF vs. Extreme                                               | PFS, OS   | Mar 2018         |

RM-HNC, relapsed metastatic head and neck cancer; Nivo, Nivolumab; IPI, ipilimumab; Extreme, extreme regimen (PF+Cetuximab); OS, overall survival; PFS, progression-free survival; PEM, pembrolizumab; TVEC, talimogene laherparepvec; PF, platinum fluorouracil.

### Table 5. Study’s toxicity

| Study                  | No. of patients | Toxicity                                                                 | AE grade 3–4 (%) | Any grade (%) |
|------------------------|-----------------|--------------------------------------------------------------------------|------------------|---------------|
| KEYNOTE-012            | Seiwert et al. (2016) [13] | Fatigue, pruritus, nausea, decreased appetite, rash                      | 9                | 45            |
| KEYNOTE-012            | Chow et al. (2016) [9]          | Fatigue, pruritus, nausea, decreased appetite, rash                      | 15               | 53            |
| CheckMate 141          | Ferris et al. (2016) [10]        | Fatigue, nausea, rash, decreased appetite, pruritus, diarrhea            | 13               | 58.9          |
| KEYNOTE-055            | Bauml et al. (2017) [37]         | Fatigue, hypothyroidism, diarrhea, pneumonitis, aspartate, aminotransferase increase | 15               | 64            |

AE, adverse events.
ed the results at a minimum follow-up of 11.4 months of CheckMate 141. What is not biological surprising is the response in 24% of patients who had experienced progression (ClinicalTrials.gov Identifier: NCT02105636). The suggestion is to continue treatment in those without clinical progression with good performance status [41].

**WHY IS THE ACTIVITY OF ICIs LIMITED?**

PD-1/PD-L1-targeted drugs have obvious advantages over traditional therapeutic regimens in terms of overall response rate, survival, and safety but their efficacy is still disappointing. As single agents, these therapies have response rates in the range of 14%–32% [11]. Several mechanisms can elicit the resistance of HNC cells to immunotherapy: (1) immunosuppressive factors in microenvironment: abundance of FoxP3+ and deregulation of CCL22-CCR4 axis has been reported [42]; constitutive activation of STAT3 and expression of VEGF, interleukin (IL)-6, IL-10. HNC inhibits chemokines in a transforming growth factor beta and VEGF dependent manner [43]. (2) Impaired human leucocyte antigen (HLA)-mediated cancer cell recognition: HNC over-express EGFR. Over-expression and over-activation of EGFR not only induces oncogenic transformations but also downregulates the expression of antigen presenting machinery. EGFR activates a protein phosphatase (SHP2) which dephosphorylates STAT1 (signal transducer and activator of transcription 1) leading to reduced HLA class I dependent antigen presentation [44]. (3) PD-1/PD-L1 expression: a downregulation is mediated in a JAK2/STAT1 dependent manner. Moreover, EGFR blockade downregulated IFN-γ-dependent PD-L1 expression according to Concha-Benavente and Ferris [44]. Interestingly, EGFR also promotes stabilization of PD-L1 surface expression through glycosylation of its extracellular domain [45]. (4) Several immune modulators were reported to negatively affect T cells activity. For example, VISTA (V-domain Ig suppressor of T cell activation), a recently discovered protein involved in the checkpoint inhibitors, is overexpressed in HNSCC [23].

In the randomized CheckMate 141 trial, PD-L1 expression was assessed on tumor cells of 72% of the patients. Patients were divided in two prespecified subgroups (expression ≥ 1% and <1%). The magnitude of survival benefit was greater in PD-L1 ≥ 1% population, hazard ratio for death 0.55 (0.36 to 0.86) vs. 0.89 (0.54 to 1.85), whereas no advantage was demonstrated for increasing PD-L1 expression [10]. The expanded cohort of the KEYNOTE-012 trial used two different methods to define PD-L1 positivity: the combined positive score (CPS) defined as ≥1% of expression in both tumor and mononuclear inflammatory cells, and the tumor proportion score defined as ≥1% of expression only in tumor cells [9]. The study identified a relation between PD-L1 positivity and relative ratio (RR) only with the combined positivity score (22% vs. 4%, P=0.021). Similarly, statistically significant differences for PFS and OS were observed for PD-L1 positive patients using CPS [13].

On the contrary, in the KEYNOTE-055 study, using the same CPS score, PD-L1 positivity was not demonstrated to be predictive of response, the response rate being 12% even in PD-L1 negative patients, compared to 18% in positive patients. Interestingly, RR was higher in patients with ≥50% [37]. In the KEYNOTE-040, Cohen et al. [14] presented the results among the difference in PD-L1 CPS score ≥1% versus the tumoral positive score ≥50%, these results confirm the role of this marker, but no comparison can be obtained among tumoral positive score and CPS as they used two different levels [14]. Therefore, PD-L1 is a marker but we cannot assume it is the marker; several factors contribute to the immune continuum and a better knowledge is required to have a reproducible and safe predictive marker. Muller et al. [47] reported a strong correlation between expression of PD-L1 and reduced OS time.

Other biomarkers appear fascinating such as PD-L1 evaluation in circulating cell (blood biopsy), characterization of tumor infiltrating cells and PD-L2. This latter was studied by Yearley et al. [48] on 180 HNSCC patients. They showed that response was greater in patients positive for both PD-L1 and PD-L2 (27.5%) than those positive only for PD-L1 (11.4%). PD-L2 status was also a significant predictor of PFS with pembrolizumab independent of PD-L1 status. Longer median times for PFS and OS were observed for PD-L2-positive than PD-L2-negative patients.

### BIOMARKERS

ML and gene expression profile (GEP) were utilized in some American institution to assess in order to identify responders. ML and GEP are independently predictive of response to pembrolizumab in HPV−/EBV− patients with HNSCC; GEP was predictive regardless of viral status [11]. ML and GEP may have utility in characterizing responses to anti-PD-1 therapies and novel cancer regimens in HNSCC. Mattox et al. [46] demonstrated, by analyzing archival tissue stained for PD-L1, that PD-L1 status in RM-HNC patients did not directly correlated, as in other solid tumors, with OS nor PFS NCT02543476.

**CONCLUSION**

Immunotherapy clearly is active in head and neck cancer, both virally related/not related and heavily pre-treated patients. Head and neck cancer shows a prominent immune phenotype. Response rates are reasonable, but they are probably underestimating benefit, impact on survival is significant in responders. Anti-PD-1 and PD-L1 agents are well tolerated but awareness of potential immune-related AEs is important. We still need robust
and consistent biomarkers. From KEYNOTE studies, we should carefully select patients avoiding those with HPV negative and PD-L1 negative tumors.

Improvement in quality of life is reported compared with chemotherapy. Combination approaches are promising, first-line combinations studies are ongoing. It is important to learn how to integrate immunotherapy with other treatments. We should argue that, in the near future, the fastest run to register all combinations will probably determine the willingness to use (if economically allowed in any center) many combinations but without a personalized medicine. The cancer immunogram by Blank et al. [16] might suggest, if combinations are needed, which one is preferable, deserving a combination to patients without significant immune cell infiltration and absence of soluble inhibitors. New options for treatment in these patients will be soon available; we should have the ability to select them and to build a flowchart.

**CONFLICT OF INTEREST**

No potential conflict of interest relevant to this article was reported.

**REFERENCES**

1. Bernier J, Domenech C, Ozsahin M, Matuszewksa K, Lefebvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004 May;350(19):1945-52.
2. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004 May;350(19):1937-44.
3. Merlano M, Vitale V, Rosso R, Benasso M, Corvo R, Cavallari M, et al. Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med. 1992 Oct;327(16):1115-21.
4. Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003 Jan;21(1):92-8.
5. al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol. 1997 Jan;15(1):277-84.
6. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010 Jan;11(1):21-8.
7. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008 Sep;359(11):1116-27.
8. Siano M, Infante G, Resteghini C, Cau MC, Alfieri S, Bergamini C, et al. Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy. Oral Oncol. 2017 Jun;69:33-7.
9. Chow LQ, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 2016 Nov;34(32):3838-45.
10. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016 Nov;375(19):1856-67.
11. Szturz P, Vermorken JB. Immunotherapy in head and neck cancer: aiming at extreme precision. BMC Med. 2017 Jun;15(1):110.
12. Segal NH, Ou SH, Balmanoukian AS, Massarelli E, Brahmer JR, Weiss J, et al. Updated safety and efficacy of durvalumab (MEDI 4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. Ann Oncol. 2016 Oct;27(suppl 6):949.
13. Seiwert TY, Burtness E, Mehra R, Weiss J, Berger R, Eder JP, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016 Jul;17(7):956-65.
14. Cohen EE, Harrington KJ, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, et al. Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): phase 3 KEYNOTE-040 trial. Ann Oncol. 2017 Sep;28(Suppl 5);v605-49.
15. Machiels JP, Haddad R, Fayette J, Licitra LF, Tahara M, Vermorken JB, et al. Aftatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015 May;16(5):583-94.
16. Blank CU, Haanen JB, Riba S, Schumacher TN. Cancer immunology: the “cancer immunogram”. Science. 2016 May;352(6286):658-60.
17. Davis RJ, Van Waes C, Allen CT. Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncol. 2016 Jul;58:59-70.
18. Lin DC, Meng X, Hazawa M, Nagata Y, Varela AM, Xu L, et al. The genomic landscape of nasopharyngeal carcinoma. Nat Genet. 2014 Aug;46(8):866-71.
19. Seiwert TY, Zuo Z, Keck MK, Khattri A, Pedamallu CS, Stricker T, et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015 Feb;21(3):632-41.
20. Barber GN. STING: infection, inflammation and cancer. Nat Rev Immunol. 2015 Dec;15(12):760-70.
21. Lin K, Qu S, Chen X, Wu Q, Shi M. Promising targets for cancer immunotherapy: TLRs, RLRs, and STING-mediated innate immune pathways. Int J Mol Sci. 2017 Feb;18(2):E404.
22. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017 Oct;377(14):1345-56.
23. Burugu S, Dancsok AR, Nielsen TO. Emerging targets in cancer immunotherapy. Semin Cancer Biol. 2018 Oct;52(Pt 2):39-52.
24. Economopoulou P, Kotsantis I, Pysrri A. The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches. ESMO Open. 2017 Feb;1(6):e000122.
25. Cohen EE, Ferris RL, Gash K, Manjarrez K, Dietsch G, Hershberg RM, et al. Active8: a randomized, double-blind, placebo-controlled
study of chemotherapy plus cetuximab in combination with VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2014;32(15 suppl):TPS3123.

26. Chow LQ, Morishima C, Eaton KD, Baik CS, Goulart BH, Anderson LN, et al. Phase Ib trial of the toll-like receptor 8 agonist, motolimod (VTX-2337), combined with cetuximab in patients with recurrent or metastatic SCCHN. Clin Cancer Res. 2017 May;23(10):2442-50.

27. Kershaw MH, Devaud C, John LB, Westwood JA, Darcy PK. Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment. Oncoimmunology. 2013 Sep;2(9):e25962.

28. Vanpouille-Box C, Formenti SC, Demaria S. Toward precision radiotherapy for use with immune checkpoint blockers. Clin Cancer Res. 2018 Jan;24(2):259-65.

29. ClinicalTrials. Pembrolizumab in combination with CRT for LA-SCCHN: NCT02586207 [Internet]. Bethesda: U.S. National Library of Medicine; [cited 2018 Mar 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02586207?term=nct02586207&rank=1.

30. ClinicalTrials. Cetuximab & Nivolumab in patients with recurrent/metastatic head & neck squamous cell carcinoma: NCT033082534 [Internet]. Bethesda: U.S. National Library of Medicine; [cited 2018 Mar 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT033082534?recrs=ab&cond=CETUXIMAB+AND+DURVALUMAB&rank=2.

31. ClinicalTrials. Pembrolizumab combined with cetuximab for treatment of recurrent/metastatic head & neck squamous cell carcinoma: NCT02124850 [Internet]. Bethesda: U.S. National Library of Medicine; [cited 2018 Mar 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02124850?recrs=ab&cond=CETUXIMAB+AND+MOTOLIMOD&rank=1.

32. ClinicalTrials. Pembrolizumab in combination with CRT for LA-SCCHN: NCT02586207 [Internet]. Bethesda: U.S. National Library of Medicine; [cited 2018 Mar 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02586207?term=nct02586207&rank=1.

33. ClinicalTrials. Pembrolizumab in combination with CRT for LA-SCCHN: NCT02586207 [Internet]. Bethesda: U.S. National Library of Medicine; [cited 2018 Mar 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02586207?term=nct02586207&rank=1.

34. ClinicalTrials. Immunotherapy with MK-3475 in surgically resectable head and neck squamous cell carcinoma: NCT02296684 [Internet]. Bethesda: U.S. National Library of Medicine; [cited 2018 Mar 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02296684?cond=Immunotherapy+with+MK-3475+in+surgically+resectable+head+and+neck+squamous+cell+cancer&rank=1.

35. Smola S, Trimble C, Stern PL. Human papillomavirus-driven immune response: challenge and novel opportunity for immunotherapists. Ther Adv Vaccines. 2017 Jun;5(3):69-82.

36. Ooft ML, van Ipenburg JA, Sanders ME, Kranendonk M, Hofland I, de Bree R, et al. Prognostic role of tumour-associated macrophages and regulatory T cells in EBV-positive and EBV-negative nasopharyngeal carcinoma. J Clin Pathol. 2018 Mar;71(3):267-74.

37. Bauml J, Seiwert TY, Pfister DG, Warden F, Liu SV, Gilbert J, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J Clin Oncol. 2017 May;35(14):1542-9.

38. Harrington KJ, Ferris RL, Blumenschein G Jr, Colevas AD, Fayette J, Licitra L, et al. Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017 Aug;18(8):1104-15.

39. Mandal S, Senbabaoğlu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight. 2016 Oct;1(17):e89829.

40. Saada-Bouzid E, Defaubeux C, Karabaskanian A, Coloma VP, Servois V, Paoletti X, et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2017 Jul;28(7):1605-11.

41. Haddad R, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: a biomarker analysis and updated clinical outcomes. Ann Oncol. 2017 Sep;28(suppl 5). https://doi.org/10.1093/annonc/mdx374.001.

42. Zhao M, Li Y, Wei X, Zhang Q, Jia H, Quan S, et al. Negative immune factors might predominate local tumor immune status and promote carcinogenesis in cervical carcinoma. Virol J. 2017 Jan;14(1):5.

43. Huang TT, Su JC, Liu CY, Shiau CW, Chen KF. Alteration of SHP-1/p-STAT3 signaling: a potential target for anticancer therapy. Int J Mol Sci. 2017 May;18(6):1234.

44. Concha-Benavente F, Ferris RL. Reversing EGF-mediated immune escape by targeted monoclonal antibody therapy. Front Pharmacol. 2017 May;8:332.

45. Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016 Aug;7:12632.

46. Mattox AK, Lee J, Westra WH, Pierce RH, Ghossein R, Faquin WC, et al. PD-1 expression in head and neck squamous cell carcinomas derives primarily from functionally anergic CD4(+) TILs in the presence of PD-L1+ TAMs. Cancer Res. 2017 Nov;77(22):6365-74.

47. Muller T, Braun M, Dietrich A, Aktekin S, Hoft S, Kristiansen G, et al. PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma. OncoTarget. 2017 May;8(32):52889-900.

48. Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin Cancer Res. 2017 Jun;23(12):3158-67.